מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
LIDOCAINE HYDROCHLORIDE
ALVEDA PHARMACEUTICALS INC
N01BB02
LIDOCAINE
10MG
SOLUTION
LIDOCAINE HYDROCHLORIDE 10MG
BLOCK/INFILTRATION
20X2/20X5/20X10/10X20/1X50ML
Ethical
LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0101280004; AHFS:
CANCELLED (UNRETURNED ANNUAL)
2024-01-08
PRESCRIBING INFORMATION LIDOCAINE HYDROCHLORIDE INJECTION, USP 1% LIDOCAINE HYDROCHLORIDE INJECTION USP 2% 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP Local Anesthetic Alveda Pharmaceuticals Inc. 40 Holly Street, Suite 801 Toronto, Ontario M4S 3C3 Submission Control No.: 150278, 152442, 152443 Date of Revision: January 4, 2012 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS......................................................................................................... 11 DRUG INTERACTIONS ......................................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................................... 16 OVERDOSAGE ....................................................................................................................... 20 ACTION AND CLINICAL PHARMACOLOGY.................................................................... 21 STORAGE AND STABILITY ................................................................................................. 23 SPECIAL HANDLING INSTRUCTIONS............................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 26 PHARMACEUTICAL INFORMATION......................................... קרא את המסמך השלם